To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Global Biomarkers Market size was valued at around USD 66.97 Billion in 2022 and is expected to rise from USD 75.88 Billion in 2023 to reach a value of USD 206.04 Billion by 2031, at a CAGR of 13.3% over the forecast period (2024–2031). 

To enhance their market share, major firms are implementing tactics including new product development, merger & acquisition, and collaboration. A number of market participants, including Abbott and F. Hoffmann-La Roche Ltd., are actively working on developing new biomarker solutions. To increase access to individualized oncology biomarker testing, Thermo Fisher Scientific, Inc. introduced CE-IVD (IVDD) NGS test and analysis software in August 2022. 'F. Hoffmann-La Roche AG (Switzerland) ', 'Thermo Fisher Scientific Inc. (United States) ', 'Agilent Technologies, Inc. (United States) ', 'QIAGEN N.V. (Netherlands) ', 'Bio-Rad Laboratories, Inc. (United States) ', 'Merck & Co., Inc. (United States)  ', 'PerkinElmer, Inc. (United States) ', 'Illumina, Inc. (United States) ', 'BD (Becton, Dickinson and Company) (United States) ', 'Myriad Genetics, Inc. (United States) ', 'Siemens Healthineers AG (Germany) ', 'Danaher Corporation (United States) ', 'Biomerieux SA (France) ', 'Waters Corporation (United States) ', 'Abbott Laboratories (United States) ', 'Sysmex Corporation (Japan) ', 'Bio-Techne Corporation (United States) ', 'Charles River Laboratories International, Inc. (United States) ', 'Eurofins Scientific SE (Luxembourg) ', 'Pacific Biomarkers (United States)'

North America accounted for the largest biomarkers market revenue share in 2023 with over 44%. 00% to factors such as the high illness burden, rising awareness of biomarkers, favorable government policies, technology advances, and enhanced health care systems. The strategic location of this area and the various organic and inorganic activities implemented by significant enterprises are key determinants expected to boost this region. For instance, in November 2023 Akoya Biosciences, Inc. launched PhenoCode signature panels for high-throughput spatial biomarker discovery.

Feedback From Our Clients

Global Biomarkers Market

Product ID: SQMIG35A2509